Moderators: Jesspro
Search This Board: 
Created: 04/23/2010 03:30:06 PM - Followers: 222 - Board type: Free - Posts Today: 0
Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need.

*Aurinia Pharmaceuticals Inc.




Candidate & Indication Development Stage
Preclinical Phase 1 Phase 2 Phase 3 Market
VOCLOSPORINLupus Nephritis (LN)
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Market Phase not started

Aurinia is committed to working in areas of high unmet medical need and is poised to deliver the first approved therapy in the U.S. and Europe for the treatment of lupus nephritis, or LN.

The Voclosporin Advantage

Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,000 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). It has been granted “fast track status” by the U.S. Food & Drug Administration (FDA).

Voclosporin Could Transform the LN treatment Landscape

Voclosporin has the potential to become a best in class medication and the first approved treatment for LN in the U.S. and Europe, effectively altering the current treatment paradigm for the disease.

Advantages of Voclosporin Combined with Standard of Care (SoC)

Our clinical data suggests that adding voclosporin to the current SoC of MMF for the treatment of lupus nephritis (LN) will yield superior results to using the standard of care alone.

Additionally, voclosporin may prove to be an ideal therapy for lupus nephritis due to advantages such as:

  • Improved efficacy
    Increased safety
    Oral administration
    Improved average time to renal response or remission
    Improved duration of renal response
    Reduction in steroid burden
    Potential first line add-on to MMF
    Fewer toxic immunosuppressants required
Benefits of Voclosporin

Potential Benefits of Voclosporin

In clinical trials, Voclosporin has been shown to be especially effective in the presence of low dose steroids with rapid reduction of LN inflammatory markers and overall improved renal stability.

The list of potential product benefits includes:

LN Critical Need Voclosporin (based on AURA Results)
Control of Active Disease
Rapid Disease Control
Lower Steroid Burden
Impact on Extra-renal disease
Convenient Treatment Regimen

In previous studies, over 2000 patients have been treated with Voclosporin with no abnormal or unexpected SAE’s

Well Characterized Safety Profile

Efficacy of calcineurin inhibition has already been established. Voclosporin has a well-characterized safety profile (over 2,000 patient exposures across multiple years) across indications.

No new safety signals were observed with the use of Voclosporin in LN patients; Voclosporin was well-tolerated and renal function remained stable in clinical studies. The overall safety profile is consistent with other immunosuppressive drugs.


PlusOneCoin Top Posts Free PlusOneCoin
No plusone'd posts yet. Be the first!
Post Subject
Grabbed more shares today. Looking forward to Cosa 09/23/2022 05:20:48 PM
All the WEF/Biden admin needs to do is greggors 09/23/2022 11:40:02 AM
Those who sell now, in my opinion, are Jesspro 09/22/2022 08:05:21 PM
Thanks Jess. I get a kick out rosemountbomber 09/22/2022 07:09:00 PM
Best post of the day: “I was wondering where biotech_researcher 09/22/2022 02:52:02 PM
His departure was rather abrupt. nsomniyak 09/21/2022 07:43:31 PM
Probably a bad point, I have swing shares Cosa 09/21/2022 04:25:29 PM
yak that is a good response thank you. cervelo 09/21/2022 04:23:57 PM
10 stocks to sell now. Jesspro 09/21/2022 03:55:25 PM
I was wondering where you were Cervelo!! Felt Newbie1421 09/20/2022 03:24:46 PM
It appears that Walbert was there only to nsomniyak 09/20/2022 02:55:59 PM
since the company wrote that and not Mr. cervelo 09/20/2022 02:45:09 PM
On September 19, 2022, Timothy P. Walbert, a longbear 09/20/2022 01:25:26 PM
Jess, I think that if that was the biotech_researcher 09/20/2022 11:32:44 AM
What Director left?? biotech_researcher 09/20/2022 11:28:46 AM
Excellent point Cosa, could not agree more Ganz 09/20/2022 09:43:19 AM
It’s not too far fetched that Voclosporin may Jesspro 09/20/2022 08:34:42 AM
I will defer to U as the board Whalatane 09/19/2022 09:20:06 PM
Yes, this was all priced in. No rosemountbomber 09/19/2022 07:22:51 PM
Jess etc all, does the departure of the longbear 09/19/2022 05:22:18 PM
50% swing opportunity here. The 3rd quarter Cosa 09/19/2022 04:56:11 PM
Was EU approval in doubt ? The challenge Whalatane 09/19/2022 03:40:24 PM
Nope. The issues with KZR are 1) Whalatane 09/19/2022 03:33:21 PM
Longbear. Thanks for that link. I bought a biotech_researcher 09/19/2022 03:26:13 PM
Jess, I bought in on 9/15 as my biotech_researcher 09/19/2022 03:24:44 PM
Geez BR. How could anyone believe you anymore? Jesspro 09/19/2022 03:06:55 PM
KZR is selling on the news! thesaud 09/19/2022 03:00:06 PM
Its a sell the news event Whalatane 09/19/2022 02:18:51 PM
Weak market response so I dumped my shares biotech_researcher 09/19/2022 02:00:08 PM
This PR was expected since 9/15. Its delay longbear 09/19/2022 01:02:53 PM
This is big news, oddly quiet on the Ganz 09/19/2022 12:03:18 PM
no reaction to sp yet. thesaud 09/19/2022 11:43:55 AM
#15797 Jesspro 09/19/2022 11:28:38 AM
JUST GOT AN ALERT! It’s approved. Jesspro 09/19/2022 11:18:47 AM
The article just says EU marketing authorization decision longbear 09/19/2022 11:02:15 AM
Probably be announced on Friday 23 at the close… greggors 09/18/2022 09:02:45 PM
yup thesaud 09/18/2022 06:28:19 PM
Thanks. So according to the article decision rosemountbomber 09/18/2022 03:51:07 PM
On the 15th when the alert came up longbear 09/17/2022 08:39:55 AM
[this article is from 7/22/2022 thesaud 09/17/2022 06:52:12 AM
I thought somebody here said the 22nd. Jesspro 09/16/2022 06:55:56 PM
I thought the EU decision was today for Lupy? biotech_researcher 09/16/2022 03:17:23 PM
Parties could also agree for a buyout Jesspro 09/15/2022 06:57:14 PM
Within 24 hours biotech_researcher 09/15/2022 06:24:36 PM
theorized BR. That’s his gut feeling. If a Jesspro 09/15/2022 06:23:38 PM
But, Jess said they were bought out.. biotech_researcher 09/15/2022 05:42:48 PM
They have a thousand ways of doing it, Jesspro 09/15/2022 04:54:09 PM
More likely, there could have been some preliminary nsomniyak 09/15/2022 04:50:50 PM
thanks longbear, why no PR from aurinia? maybe tomorrow thesaud 09/15/2022 04:36:42 PM
“One poster in ST has theorized that the biotech_researcher 09/15/2022 04:30:30 PM
Post Subject